D&D Companies

    • Developing potential therapies for
      Parkinson’s and Alzheimer’s disease
    • Lead asset NLY01, microglia-targeted
      GLP1R agonist
    • Developing potential imaging biomarkers for CNS disorders and cancer
    • Lead assets, various PET imaging
      agents for neuroinflammation (PD, AD
      and ALS) and cancer
    • Building the world’s largest collection
      of single-cell information derived from
      diseased post-mortem brain tissues
    • Identifying biomarkers for therapy
      and early diagnosis of
      neurodegenerative diseases using big
      data and machine learning
    • Developing potential therapies for
      fibrosis and fibrosis-driven cancer
    • Lead asset TLY012, first-in-class
      myofibroblast-targeted DR5 agonist
    • Developing potential treatments for
      periodontal diseases and
      gastrointestinal disease including IBS
    • Lead asset P4M01, antimicrobial
      peptide for gingivitis licensed
      from the US Army

Neuraly

  • Technology

    Neuraly is a clinical-stage company whose mission is to translate scientific discoveries in neurology into revolutionary new
    drugs that can radically improve and prolong the lives of people suffering from the devasting consequences of diseases such as
    Parkinson’s disease (PD), Alzheimer’s disease (AD), and other neurodegenerative disorders.

    Neuraly was founded in 2016 to translate on the foundational research by world class neuroscientists led by Ted M. Dawson,
    M.D., Ph.D., Leonard and Madlyn Abramson Professor and Director of Institute for Cell Engineering at the Johns Hopkins School
    of Medicine. Neuraly has accumulated a wealth of knowledge in the role of glia biology in neuroinflammation and
    neuroprotection as well as success in advancing a risk-diversified product portfolio for PD and AD.

    NLY01, the lead asset, is a peptide-based drug that targets microglia/astrocytes-induced neuroinflammation
    and has proven strong therapeutic efficacy in preclinical models of both PD and AD.

  • Publications

    • The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. Movement Disorders. 34(7): 959-969 (2019).
    • Promising disease-modifying therapies for Parkinson’s disease. Science Translational Medicine. 11(520) (2019).
    • Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron. 103(4): 627-641 (2019).
    • Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nature Medicine. 24:931–938 (2018).
    • Fire prevention in the Parkinson’s disease brain. Nature Medicine. 24:900–902 (2018).
    • Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease. Science. 362(6414) (2018).
    • A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science. 354(6308) (2016).
    • Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. Journal of Clinical Investigation. 126(8):2970-2988. (2016)
  • Pipeline

    Program Drug Mechansim Indication Discovery Preclinical IND Phase 1 Phase 2
    NLY01 - PD
    GLP1R agonist
    Parkinson’s disease
    NLY01 - D
    GLP1R agonist
    Type 2 diabetes
    NLY01 - AD
    GLP1R agonist
    Alzheimer's disease
    NLY02
    Drug Mechanism
    Parkinson’s disease/ AD
    NLY03
    Undisclosed
    Neurodegenerative disease
  • Date Company Title Download Language
    2020-09-24 Neuraly Fire prevention in the Parkinson’s disease test DOWNLOAD EN

PRECISION MOLECULAR

  • Technology

    Precision Molecular (PMI) is a clinical-stage company with the mission to develop imaging biomarkers and theranostics
    (targeted therapy combined with diagnostics) for management of patients with CNS disorders and cancer.

    PMI was founded in 2019 by Martin G. Pomper, M.D., Ph.D, Henry N. Wagner, Jr. Professor and Director of the Division of Nuclear
    Medicine and Molecular Imaging at the Johns Hopkins School of Medicine. PMI’s foundational intellectual property was developed by
    his world class radiology research team, known as the Precision Molecular Imaging Coalition.

    PMI features various imaging biomarker products in the clinic with great potential to improve early diagnostics of neurodegenerative
    diseases and cancer. Utilizing these imaging biomarkers to follow disease progression may provide clinical researchers with
    powerful tools for early assessment of drug efficacy in clinical trials.

  • Publications

    • Discussions with Leaders: A Conversation Between Martin Pomper and Peter Choyke. Journal of Nuclear Medicine. 61(1):3-5 (2020).
    • Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation. 129(2):616-630 (2019).
    • PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). PNAS 116(5)1686-1691 (2019).
    • Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players.
      JAMA Neurology 74(1):67-74 (2017).
    • 18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase. Journal of Molecular Imaging. 57(11)1817-1822 (2016).
    • Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.
      Journal of Nuclear Medicine.
  • Pipeline

    Program Drug Mechansim Indication Discovery Preclinical IND Phase 1 Phase 2
    PMI01
    TSPO targeting PET/SPECT tracer
    Neuroinflammation
    PMI03
    TsEH targeting PET tracer
    Neuroinflammation
    PMI04
    CSF1R targeting PET/SPECT tracer
    Neuroinflammation
    PMI05
    CAIX targeting PET/SPECT tracer
    Oncology
    PMI06
    PET ligand targeting PD-L1
    immuno-oncology
    PMI06
    PD-L1 targeting PET tracer
    Oncology
  • Date Company Title Download Language
    2020-09-24 PMI Top biotech money raisers of 2019 EN

Valted Seq

THERALY FIBROSIS

  • Technology

    Theraly is a preclinical-stage company whose mission is to develop innovative treatments for various forms of
    life-threatening fibrotic disease.

    Theraly was founded in 2015 by Seulki Lee, PhD, Associate Professor of Radiology at the Johns Hopkins School of Medicine.
    Theraly’s founding programs are based on the discoveries of Dr. Lee’s research team, whose pioneering research
    has elucidated a TRAIL biology pathway underlying the origins of disease in tissue remodeling and fibrosis.
    The company is focused on developing a potentially universal anti-fibrotic drug.

    The lead asset TLY012, a human protein-based drug, selectively targets myofibroblasts, one of the significant
    originators of fibrosis, and reverses established fibrosis in preclinical models of fibrosis in liver, pancreas, andskin.
    TLY012 has the potential to cure fibrotic diseases, including systemic sclerosis, liver fibrosis/cirrhosis, and
    chronic pancreatitis, as well as fibrosis driven cancers.

  • Publications

    • Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. Nature Communications 10:1128 (2019).
    • Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Hepatology. 64(1):209-223 (2016).
    • Paving the TRAIL to anti‐fibrotic therapy. Hepatology. 64(1):29-31 (2016).
  • Pipeline

    Program Drug Mechansim Indication Discovery Preclinical IND Phase 1 Phase 2
    TLY012
    DR5 agonist
    NASH-liver fibrosis
    TLY012
    DR5 agonist
    Chronic pancreatitis
    TLY012
    DR5 agonist
    Systemic sclerosis
    TLY014
    Undisclosed
    Pancreatic cancer
  • Date Company Title Download Language
    2020-09-24 Theraly Top biotech money raisers of 2019 EN

P4Microbiome

  • Pipeline

    Program Drug Mechansim Indication Discovery Preclinical IND Phase 1 Phase 2
    P4M01
    Antibacterial
    Periodontal disease
  • Date Company Title Download Language
    2020-09-24 P4M Top biotech money raisers of 2019 EN